Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tocilizumab Versus Baricitinib in Hospitalized Patients With Severe COVID-19: an Open-label, Randomized Controlled Trial

NCT05082714 is registered in ClinicalTrials.gov with University Hospital of Patras as lead sponsor.

NCT NCT05082714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05082714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tocilizumab Versus Baricitinib in Hospitalized Patients With Severe COVID-19: an Open-label, Randomized Controlled Trial
Lead sponsor
University Hospital of Patras
Phase
Not applicable
Overall status
Completed
Start date
October 20, 2021
Completion date
June 4, 2022
Enrollment
251 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19